Abstract:Peptides are ideally suited to mimic natural ligands and thereby function in an antagonistic or agonistic way. Furthermore they are able to physiologically disrupt functional complexes due to their small size and specific binding properties. Proteins form homo- or heteromeric (macro)molecular complexes and intricate networks by interacting with small molecules, peptides, nucleic acids or other proteins. On average, five interaction partners have been estimated for any given cellular protein, illustrating the complexity of the formed 'interactomes' and the impact of their investigation. Many protein-protein interactions are mediated by hot-spots, which comprise only a small part of the large binding interface but account for 80% of the binding energy. Thus, these hot spots provide an 'Achilles heel' for pharmaceutical interventions aiming at the disruption of functional protein-protein complexes. Methods to select peptides for defined target structures include display technologies on phages, ribosomes or yeast, and the yeast-two-hybrid system. Once selected, these peptides can be optimized for their binding affinity using peptide arrays. Stabilization of biologically unstable peptides is achieved by the introduction of non-natural amino acids to form so-called peptidomimetics that are resistant to cellular proteases. Moreover, lipocalins and peptide aptamers represent scaffolded binding structures with unique binding characteristics and enhanced stability. In case of extracellular targets, like cell surface receptors or pathogens in patients` plasma, peptide inhibitors have direct access. Addressing intracellular targets with peptides is more difficult since short hydrophilic peptides generally do not cross plasma membranes on their own. However, intracellular uptake of peptides can be achieved by coupling to carrier systems like liposomes or nanoparticles or upon fusion to a protein transduction domain. Alternatively, peptides may be expressed within cells after transduction with viral vectors in a gene therapy setting. This review will summarize the broad potential of peptides as drugs, with special emphasis on peptides which inhibit protein-protein interactions.

Peptides as Targeting Agents and Therapeutics: A Brief Overview

Novel Peptide Therapeutic Approaches for Cancer Treatment

Peptides as drugs: from screening to application

Peptide therapeutics: Targeting the undruggable space

Peptides for therapeutic applications – challenges and chances

Recent advances and applications of peptide–agent conjugates for targeting tumor cells

Peptide Drugs: Current Status and it's Applications in the Treatment of Various Diseases

Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems

Applications of Peptide-based Nanomaterials in Targeting Cancer Therapy

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Mechanisms Inspired Targeting Peptides

Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications

Peptides-based therapy and diagnosis. Strategies for non-invasive therapies in cancer

Toxins and Derivatives in Molecular Pharmaceutics: Drug Delivery and Targeted Therapy.

Peptide-Based Biomaterials for Combatting Infections and Improving Drug Delivery

The Potential Use of Peptides in Cancer Treatment

Peptide-Based Therapeutics in Cancer Therapy

Cancer Treatment Using Peptides: Current Therapies and Future Prospects

Design of Cell-Specific Targeting Peptides for Cancer Therapy

Peptides in Cancer Nanomedicine: Drug Carriers, Targeting Ligands and Protease Substrates.

Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy